X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
0
South Africa
0
Uploaded Dossiers
U.S. Medicaid
Annual Reports
0
0
https://www.globenewswire.com//news-release/2023/10/20/2763975/0/en/Avadel-Pharmaceuticals-Announces-Data-Supporting-Clinical-Profile-for-LUMRYZ-sodium-oxybate-for-extended-release-oral-suspension-CIII-at-World-Sleep-2023.html
https://endpts.com/avadel-launches-quick-start-to-narcolepsy-drugs-marketing-after-long-road-to-approval/
https://www.fiercepharma.com/pharma/jazz-sues-fda-over-approval-rival-avadels-narcolepsy-drug-lumryx
https://www.globenewswire.com/news-release/2023/06/22/2692845/0/en/Avadel-Pharmaceuticals-to-Host-Commercial-Day-on-June-29-for-LUMRYZ-sodium-oxybate-extended-release-for-oral-solution-CIII.html
https://www.prnewswire.com/news-releases/da-pharma--despite-the-latest-alarming-figures-on-alcohol-dependence-france-is-delaying-the-use-of-sodium-oxybate-which-has-been-prescribed-for-almost-30-years-in-italy-and-austria-301857801.html
https://www.globenewswire.com/news-release/2023/06/05/2681807/0/en/Avadel-Pharmaceuticals-Announces-U-S-Commercial-Launch-of-LUMRYZ-sodium-oxybate-for-the-Treatment-of-Cataplexy-or-Excessive-Daytime-Sleepiness-in-Adults-Living-with-Narcolepsy.html
https://endpts.com/fda-approves-avadels-narcolepsy-drug-after-courts-forced-jazz-patent-delisting/
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=214755
https://www.globenewswire.com/news-release/2023/05/01/2658536/0/en/Avadel-Pharmaceuticals-Announces-Final-FDA-Approval-of-LUMRYZ-sodium-oxybate-for-Extended-Release-Oral-Suspension-as-the-First-and-Only-Once-at-Bedtime-Oxybate-for-Cataplexy-or-Exc.html
https://www.reuters.com/legal/jazz-pharma-ruling-clears-us-roadblock-rival-narcolepsy-drug-2023-02-24/
https://www.expresspharma.in/hikma-pharma-launches-xyrems-generic-in-us/
https://www.fiercepharma.com/pharma/jazz-case-ftc-urges-court-delist-patent-blockbuster-xyrem
https://www.globenewswire.com/news-release/2021/06/09/2244435/0/en/Avadel-Presents-New-Clinical-Data-from-Pivotal-Phase-3-REST-ON-Trial-Supporting-Clinical-Benefit-of-FT218-in-Patients-with-Narcolepsy-at-SLEEP-2021.html
https://www.prnewswire.com/news-releases/jazz-pharmaceuticals-announces-sleep-publication-of-phase-3-xywav-calcium-magnesium-potassium-and-sodium-oxybates-oral-solution-study-in-cataplexy-or-excessive-daytime-sleepiness-in-patients-with-narcolepsy-301155706.html
https://www.globenewswire.com/news-release/2020/09/14/2092897/0/en/Avadel-Pharmaceuticals-Announces-FT218-Leadership-Transition.html#:~:text=Avadel%20Pharmaceuticals%20Announces%20FT218%20Leadership%20Transition,-Email%20Print%20Friendly&text=will%20be%20stepping%20down%20as,for%20FT218%20with%20the%20FDA.
https://www.prnewswire.com/news-releases/jazz-pharmaceuticals-to-present-new-data-on-xywav-calcium-magnesium-potassium-and-sodium-oxybates-oral-solution-and-sunosi-solriamfetol-at-virtual-sleep-2020-301119658.html
https://www.prnewswire.com/news-releases/jazz-pharmaceuticals-announces-us-fda-approval-of-xywav-calcium-magnesium-potassium-and-sodium-oxybates-oral-solution-for-cataplexy-or-excessive-daytime-sleepiness-associated-with-narcolepsy-301097861.html
https://www.fiercebiotech.com/biotech/jazz-s-xyrem-follow-up-flies-through-phase-3-poised-for-2020-launch
https://endpts.com/as-investors-fret-about-xyrem-durability-jazz-spends-52m-upfront-to-swallow-neuro-focused-biotech/
https://www.fiercepharma.com/pharma/pfizer-never-say-never-m-a-buys-oncology-innovator-array-for-11-4b
https://www.fiercepharma.com/pharma/jazz-plans-early-july-launch-for-sleepiness-med-sunosi-after-dea-scheduling
https://www.raps.org/news-and-articles/news-articles/2019/1/eu-regulatory-roundup-mhra-finalizes-position-on?utm_source=MagnetMail&utm_medium=Email%20&utm_campaign=RF%20Today%20%7C%203%20January
http://www.prnewswire.co.uk/news-releases/jazz-pharmaceuticals-announces-fda-approval-of-xyrem-sodium-oxybate-for-the-treatment-of-cataplexy-or-698878911.html
https://www.reuters.com/article/us-jazz-amneal-patent/u-s-court-denies-jazz-pharma-bid-to-revive-patents-on-narcolepsy-drug-idUSKBN1K326D
https://www.biospectrumasia.com/news/25/11170/jazz-pharma-gets-fda-nod-for-xyrem-to-treat-cataplexy-and-eds.html
https://www.prnewswire.com/news-releases/jazz-pharmaceuticals-announces-fda-acceptance-of-supplemental-new-drug-application-for-xyrem-sodium-oxybate-to-treat-cataplexy-and-excessive-daytime-sleepiness-in-pediatric-narcolepsy-patients-300673522.html
https://www.pharmacompass.com/pdf/news/xyremsodium-oxybate-jazz-pharmaceuticals-v-lupin-1525071319.pdf
https://www.pharmacompass.com/pdf/news/xyrem-sodium-oxybate-jazz-pharmaceuticals-v-mallinckrodt-1517210713.pdf
https://www.pharmacompass.com/pdf/news/xyrem-sodium-oxybate-jazz-pharmaceuticals-v-ascent-pharmaceuticals-inc-1501486551.pdf
https://www.bloomberg.com/news/articles/2017-07-06/rare-disease-drugmakers-join-in-worries-over-gop-health-overhaul
https://www.pharmacompass.com/pdf/news/xyrem-sodium-oxybate-jazz-pharmaceuticals-v-amneal-pharmaceuticals-1494838905.pdf
http://www.prnewswire.com/news-releases/jazz-pharmaceuticals-reaches-settlement-with-hikma-pharmaceuticals-related-to-xyrem-patent-litigation-300435524.html
http://www.prnewswire.com/news-releases/jazz-pharmaceuticals-announces-first-patient-enrolled-in-phase-3-clinical-study-evaluating-jzp-258-for-the-treatment-of-cataplexy-and-excessive-daytime-sleepiness-in-narcolepsy-300424223.html
http://seekingalpha.com/article/4053368-avadel-pharmaceuticals-buy-17-price-target
http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=203351
http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=203631
http://www.reuters.com/article/us-fda-approval-xyrem-idUSKBN15133P
http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202090
https://globenewswire.com/news-release/2017/01/03/902965/0/en/Avadel-Pharmaceuticals-Appoints-Gregory-J-Divis-Chief-Commercial-Officer.html
http://www.fiercepharma.com/marketing/noted-price-hiker-jazz-feels-heat-as-pto-strikes-xyrem-patents
http://www.fiercebiotech.com/biotech/after-holiday-weekend-rumors-jazz-confirms-1-5b-buyout-tiny-celator
http://www.reuters.com/article/us-amarin-fda-settlement-idUSKCN0WA2PK
http://www.forbes.com/sites/johnosborn/2015/08/07/a-cold-wind-blows-through-the-corridors-of-the-fda-federal-judge-grants-amarin-injunction/
http://www.fdalawblog.net/fda_law_blog_hyman_phelps/2015/02/whos-recommendations-to-schedule-gbl-and-1-4-butanediol-under-international-drug-control-treaty-woul.html
http://www.flamel.com/wp-content/uploads/2014/12/Flamel-announces-Second-Clinical-Trial-with-Micropump-Sodium-Oxybate-20141219.pdf
Market Place
Share 
